Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines

Allergy. 2014 Jan;69(1):132-5. doi: 10.1111/all.12234. Epub 2013 Oct 10.

Abstract

Omalizumab, a monoclonal antibody targeting IgE, is an established therapy for severe allergic asthma and has shown efficacy in chronic spontaneous urticaria. Small-scale studies indicated some beneficial effect also in atopic dermatitis (AD). To evaluate the efficacy of omalizumab in AD and to identify markers associated with treatment response, we conducted a prospective 28-week open-label trial on 20 adults with moderate-to-severe AD. Our results confirm previous observations of a positive response in a subgroup of patients and suggest that responders are characterized by the absence of filaggrin mutations and altered lipid metabolite profiles with high levels of various glycerophospholipids.

Keywords: anti-IgE; atopic dermatitis; filaggrin; metabolomics; omalizumab.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Allergic Agents / therapeutic use
  • Antibodies, Anti-Idiotypic / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Dermatitis, Atopic / blood*
  • Dermatitis, Atopic / drug therapy
  • Dermatitis, Atopic / genetics*
  • Filaggrin Proteins
  • Humans
  • Intermediate Filament Proteins / genetics*
  • Omalizumab
  • Phosphatidylcholines / blood*
  • Treatment Outcome

Substances

  • Anti-Allergic Agents
  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal, Humanized
  • FLG protein, human
  • Filaggrin Proteins
  • Intermediate Filament Proteins
  • Phosphatidylcholines
  • Omalizumab